Encouraged by the great success of PARP inhibitors in maintenance therapy for ovarian cancer (10), several studies on PARP inhibitors for maintenance therapy after first-line chemotherapy in advanced or metastatic UC have been gradually conducted. This evidence concerns the gene PARP1 and ovarian cancer.